PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1550566
PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1550566
Global leuprolide acetate market is estimated to be valued at USD 3.82 Billion in 2024 and is expected to reach USD 5.81 Billion by 2031, exhibiting a compound annual growth rate (CAGR) of 6.2% from 2024 to 2031.
Report Coverage | Report Details | ||
---|---|---|---|
Base Year: | 2023 | Market Size in 2024: | US$ 3.82 Bn |
Historical Data for: | 2019 to 2023 | Forecast Period: | 2024 to 2031 |
Forecast Period 2024 to 2031 CAGR: | 6.20% | 2031 Value Projection: | US$ 5.81 Bn |
Global leuprolide acetate market refers to the pharmaceutical market for leuprolide acetate drugs, which is a synthetic nonapeptide analog of naturally occurring gonadotropin-releasing hormone (GnRH). Leuprolide acetate is used as a medication to treat prostate cancer, breast cancer, endometriosis and uterine fibroids. As an agonist of gonadotropin-releasing hormone (GnRH) receptor, leuprolide acetate works by reducing the secretion of FSH and LH from the pituitary gland which helps in treatment of above-mentioned conditions. Increasing incidence of cancers and other disorders for which leuprolide acetate is used as a therapeutic drug can drive the global leuprolide acetate market growth during the forecast period.
Rising prevalence of prostate cancer, breast cancer, endometriosis and uterine fibroids across the globe can drive the global leuprolide acetate market growth. According to World Cancer Research Fund, prostate cancer is the second most commonly diagnosed cancer in men globally. Favorable drug approval scenario and increasing healthcare expenditure in developing nations can drive the market growth. However, high costs associated with leuprolide acetate drugs and preference of alternative treatment options in some countries can hamper the market growth. Ongoing research & development activities for development of innovative drug delivery systems of leuprolide acetate can provide potential opportunities for market players in the near future.
This report provides in-depth analysis of the global leuprolide acetate market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global leuprolide acetate market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Takeda Pharmaceuticals, Livzon Pharmaceutical, Beijing Biote, Sanofi, Sun Pharmaceutical, AbbVie, and Pfizer.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global leuprolide acetate market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global leuprolide acetate market
Detailed Segmentation-